Target intelligence / Profile preview

Nodules

Molecular classification
Anatomical structure, Clinical manifestation, Pathological finding
01

Overview

Nodules are localized, often spherical anatomical or pathological structures that form within various tissues and organs. In clinical medicine, they are most commonly identified as lung, thyroid, or rheumatoid nodules and can be benign (inflammatory) or malignant (cancerous) [20, 23]. While 'nodules' are not specific molecular targets themselves, they serve as critical diagnostic and therapeutic endpoints; for example, the regression of rheumatoid nodules is a key indicator of efficacy for Janus kinase (JAK) inhibitors such as tofacitinib [4]. In oncology, the detection and molecular profiling of nodules (e.g., identifying BRAF or RET mutations in thyroid nodules) guide the administration of targeted tyrosine kinase inhibitors [1, 3]. In plant biology, root nodules are specialized organs formed through symbiotic interactions with nitrogen-fixing bacteria, involving specific signaling molecules called nodulins and nodulation receptor kinases [10, 11, 13]. Because the term describes a macroscopic or microscopic structure rather than a discrete protein or receptor, it is not considered a molecular therapeutic target in the traditional sense [1, 23].

Other names
Anatomical nodulesClinical nodulesPathological nodulesPulmonary nodulesThyroid nodulesRheumatoid nodulesRoot nodulesMeiotic nodulesActin nodules
02

Mechanism of action

Nodules are physical structures and not molecular targets; however, drugs targeting molecules within them (e.g., kinases or cytokines) can lead to nodule regression or are used for targeted imaging [4, 8, 12].

03

Biological functions

InflammationTumorigenesisSymbiotic nitrogen fixationMeiotic recombinationCellular adhesion
04

Disease associations

CancerInflammationRheumatoid arthritisInfectionFibrosis
05

Safety considerations

Invasive biopsy-related complicationsDiagnostic uncertainty of indeterminate nodulesRisk of misclassifying malignant lesions as benignAccelerated nodulosis as a paradoxical drug side effect
06

Interacting drugs

Sorafenib

6 more in the full profile.

07

Biomarkers

Nodule diameter and volumeNodule density (Hounsfield units)Calcification patternsFine-needle aspiration (FNA) cytologyBRAF V600E mutationFolate receptor alpha (FRα)Thyroid-stimulating hormone (TSH)

Beyond the preview

Go deeper on Nodules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nodules.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call